Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Authors: Oh, Do-Youn ^{a, b, *}, He, Aiwu Ruth ^c, Bouattour, Mohamed ^d, Okusaka, Takuji ^e, Qin, Shukui ^f, Chen, Li-Tzong ^{g, h, i}, Kitano, Masayuki ^j, Lee, Choong-kun ^k, Kim, Jin Won ^l, Chen, Ming-Huang ^m, Suksombooncharoen, Thatthan ⁿ, Ikeda, Masafumi ^o, Lee, Myung Ah ^p, Chen, Jen-Shi ^q, Potemski, Piotr ^r, Burris, Howard A, III ^s, Ostwal, Vikas ^t, Tanasanvimon, Suebpong ^u, Morizane, Chigusa ^v, Zaucha, Renata E ^w, McNamara, Mairéad G ^x, Avallone, Antonio ^y, Cundom, Juan E ^z, Breder, Valeriy ^aa, Tan, Benjamin ^ab, Shimizu, Satoshi ^ac, Tougeron, David ^ad, Evesque, Ludovic ^ae, Petrova, Mila ^af, Zhen, David B ^ag, Gillmore, Roopinder ^ah, Gupta, Vineet Govinda ^ai, Dayyani, Farshid ^aj, Park, Joon Oh ^ak, Buchschacher, Gary L, Jr ^al, Rey, Felipe ^am, Kim, Hyosung ^an, Wang, Julie ^ao, Morgan, Claire ^ap, Rokutanda, Nana ^ap, Żotkiewicz, Magdalena ^aq, Vogel, Arndt ^{ar, as}, Valle, Juan W ^{x, at}

Source: In The Lancet Gastroenterology & Hepatology August 2024 9(8):694-704